NCT04536688View on ClinicalTrials.gov

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

November 12, 2021

Study Completion Date

November 12, 2021

Conditions
Polycystic Kidney Disease, Autosomal Dominant
Interventions
DRUG

RGLS4326

Solution for subcutaneous injection

Trial Locations (12)

32701

Accel Research Sites- Mid-Florida Kidney and Hypertension Care, Altamonte Springs

48066

St. Clair Nephrology Research, Roseville

55904

Mayo Clinic, Rochester

66160

University of Kansas Medical Center, Kansas City

75390

UT Southwestern Medical Center, Dallas

78209

ICON Early Phase Services, San Antonio

90022

Academic Medical Research Institute, Los Angeles

91942

Balboa Nephrology Medical Group, La Mesa

98104

Swedish Polycystic Kidney Disease Center, Seattle

06510

Yale Nephrology Clinical Research, New Haven

02111

Tufts Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Regulus Therapeutics Inc.

INDUSTRY

NCT04536688 - A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter | Biotech Hunter